The aim of this Acute Leukemia Working Party (ALWP) study from the European Society for Blood and Marrow Transplantation (EBMT), was to elucidate the prognostic value of TP53 mutations in patients with AML in first complete remission (CR1) that undergo an allo‐SCT and to identify any further determinants of transplant outcomes in this subgroup of patients. Here, TP53 is linked to acute myeloid leukemia.